Literature DB >> 7395625

The affinities of ergot compounds for dopamine agonist and dopamine antagonist receptor sites.

M Goldstein, J Y Lew, A Sauter, A Lieberman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7395625

Source DB:  PubMed          Journal:  Adv Biochem Psychopharmacol        ISSN： 0065-2229


× No keyword cloud information.
  5 in total

1.  Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole.

Authors:  P M Carvey; S Pieri; Z D Ling
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Bromocriptine inhibits adipogenesis and lipogenesis by agonistic action on α2-adrenergic receptor in 3T3-L1 adipocyte cells.

Authors:  Rajib Mukherjee; Jong Won Yun
Journal:  Mol Biol Rep       Date:  2012-12-28       Impact factor: 2.316

3.  Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides.

Authors:  K Fuxe; L F Agnati; C Köhler; D Kuonen; S O Ogren; K Andersson; T Hökfelt
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

Review 4.  Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Authors:  Amy F T Arnsten; Ragy R Girgis; David L Gray; Richard B Mailman
Journal:  Biol Psychiatry       Date:  2016-01-18       Impact factor: 13.382

5.  Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.

Authors:  K Jellinger
Journal:  J Neurol       Date:  1982       Impact factor: 4.849
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.